VerityRank
Alcon Inc.
Company VerifiedSwitzerland

Alcon Inc.

Alcon

Alcon Inc. is a Swiss eye-care company headquartered in Geneva and founded in 1945. It became an independent public corporation on April 9, 2019, through a 100% spin-off from Novartis AG, and has no controlling shareholder; BlackRock holds 6.5% of voting rights, UBS Fund Management 5.85%, and Vanguard 3.8%. The company employs about 25,000 people, operates in 56 countries, and serves more than 260 million patients and consumers across over 140 countries. It is listed on the SIX Swiss Exchange under ticker ALC and on the NYSE under ALC. For FY2025 it reported revenue of USD 10.401 billion, net income of USD 0.98 billion, total assets of CHF 31.555 billion, and equity of CHF 22.035 billion.

Strengths: Alcon holds the broadest portfolio in ophthalmic devices and ocular pharmaceuticals, spanning surgical equipment (Centurion, Constellation), intraocular lenses (PanOptix, Clareon, Vivity), contact lenses (Dailies Total1, Precision1, Total30, Air Optix), and ocular health products (Systane, Pataday, Rocklatan, Rhopressa). Its 18 major manufacturing and R&D facilities, anchored by the Fort Worth campus, support scale in a category where sterility and precision matter. Revenue grew from USD 8.291 billion in FY2021 to USD 10.401 billion in FY2025, a 25.4% increase that outpaced most device peers. The 2026 acquisition of Neurotech and ENCELTO adds the only FDA-approved treatment for MacTel Type 2, extending the company into retinal pharmaceuticals.

Weaknesses: Profitability is thin relative to revenue: FY2025 net income of USD 0.98 billion represents a 9.4% margin, and FY2024 net income of USD 1.018 billion was slightly lower despite revenue growth. The company faces direct competition from Johnson & Johnson Vision, Bausch + Lomb, Cooper Companies, Carl Zeiss Meditec, and Hoya, limiting pricing power in contact lenses and surgical consumables. Its 2019 spin-off left no controlling shareholder, so strategy is subject to dispersed institutional ownership, with BlackRock alone at 6.5%. Regulatory exposure is concentrated in FDA and EU device approvals, where the ENCELTO and BRYTLY launches depend on post-approval execution.

Read More
SwitzerlandFounded 194525000Headquartered in Geneva… / 100
Listed onSIXALCNYSEALC
Last updated: 2026-11-20 11:45 ET·By VerityRank Research Team·Methodology

Listed market data

2 Listings · weeklyHistory →
Market cap
$37.5 B
Share price
CHF 62.28
1Y change
+3.4%
Recent change
-1.3%

11-20

Since first close
+24.6%

from 2019-04

Revenue (TTM)
$10.4 B
SIX: ALC · Revenue FY 2025 · updated 2026-11-20 11:45 ETSource ↗

Financial history

Full market history
CHF 0$0CHF 20$12.5 BCHF 40$25.0 BCHF 60$37.5 BCHF 80$50.0 B2025-122026-012026-022026-032026-042026-052026-062026-072026-082026-092026-102026-11
MonthCloseMarket capChange
  • 2026-11CHF 62.28$37.5 B+5.4%
  • 2026-10CHF 59.10$35.6 B+9.5%
  • 2026-09CHF 53.98$32.5 B-7.8%
  • 2026-08CHF 58.56$35.2 B+5.7%
  • 2026-07CHF 55.38$33.3 B+1.4%
  • 2026-06CHF 54.60$32.9 B+4.8%
  • 2026-05CHF 52.10$31.4 B-10.5%
  • 2026-04CHF 58.22$35 B-1.8%
  • 2026-03CHF 59.26$35.7 B-11.4%
  • 2026-02CHF 66.86$40.2 B+7.1%
  • 2026-01CHF 62.42$37.6 B-1.4%
  • 2025-12CHF 63.28$38.1 B—
Monthly closes · 2025-12 – 2026-11 · Full market history

Ownership & Control

Shareholding as of 2026-11-19
Controlling entity
Publicly traded Swiss corporation with a broad institutional shareholder base and no controlling shareholder.
Company type
Company
Insiders
0.19%
Institutions
66.17%(1,176 holders)
Free float
99.74%

Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.

In the press

All coverage →4 latest headlines
Headlines aggregated from public feeds. Sentiment tags are keyword-based, not editorial judgement.

Alcon occupies the broadest position in eye care among listed companies, combining surgical equipment, intraocular lenses, contact lenses, and ocular pharmaceuticals. Its scale, with USD 10.401 billion in FY2025 revenue and 25,000 employees, places it ahead of Bausch + Lomb and Cooper Companies in combined surgical and vision-care scope, though it trails Johnson & Johnson Vision in contact lens share and Carl Zeiss Meditec in surgical visualization.

Industry Position

The eye-care market rewards installed-base economics: surgical platforms such as Centurion and Constellation generate recurring consumable revenue, and intraocular lenses attach to cataract procedures that rise with aging populations. Alcon's direct presence in 56 countries and reach across more than 140 countries gives it distribution depth that smaller competitors such as Glaukos and Santen cannot match. In contact lenses, it competes with Johnson & Johnson Vision, Cooper Companies, and Bausch + Lomb, where brand loyalty and practitioner fitting relationships determine share. In ocular pharmaceuticals, AbbVie and Bausch + Lomb are the principal rivals, and Alcon's 2026 move into retinal treatment through ENCELTO marks a shift toward higher-value specialty drugs.

The company's financial trajectory shows steady top-line expansion: revenue rose from USD 8.291 billion in FY2021 to USD 10.401 billion in FY2025, a 25.4% increase over four years. Net income has not kept pace, moving from USD 0.376 billion in FY2021 to USD 0.98 billion in FY2025, with a dip to USD 1.018 billion in FY2024 and USD 0.974 billion in FY2023. That pattern suggests margin pressure from manufacturing complexity and launch costs rather than demand weakness.

Competitive Advantages

Alcon's strongest asset is portfolio breadth. No single competitor spans surgical platforms, intraocular lenses, contact lenses, and prescription eye drops at comparable scale. The PanOptix and Vivity lens families give it a premium intraocular position, while Dailies Total1 and Precision1 anchor the daily contact lens segment. The 18 major manufacturing and R&D facilities, including the Fort Worth campus, provide redundancy and process control in a category where sterility failures are costly. The Hydrus Microstent adds a minimally invasive glaucoma option that complements its surgical installed base.

The 2026 acquisitions and approvals extend the franchise. Neurotech and ENCELTO bring the only FDA-approved treatment for MacTel Type 2, opening a retinal pharmaceutical channel. BRYTLY, approved in October 2026 for up to 12 hours of redness relief, adds an over-the-counter product with consumer reach. UNITY M, launched in September 2026, strengthens the surgical visualization line. These launches matter because they raise the share of revenue from proprietary, higher-margin products and reduce reliance on mature contact lens brands.

Strategic Expansion

The expansion strategy points toward combining devices with drugs. ENCELTO is a surgical-delivery retinal treatment, and its acquisition implies Alcon intends to sell it through existing surgical relationships rather than build a separate pharmaceutical sales force. That leverages the Centurion and Constellation installed base and the Fort Worth R&D campus. The BRYTLY approval extends the Systane and Pataday consumer health line into redness relief, a high-frequency category where brand recognition drives repeat purchase. UNITY M and UNITY VCS deepen the surgical visualization offering, which supports equipment pull-through for consumables.

Geographically, the company already operates in 56 countries directly and reaches more than 140, so incremental growth depends on premium product mix rather than new market entry. The absence of a controlling shareholder since the April 2019 Novartis spin-off means management sets strategy under dispersed institutional ownership, with BlackRock at 6.5%, UBS Fund Management at 5.85%, and Vanguard at 3.8%. That structure favors capital discipline but offers no parent backstop for large acquisitions.

Risks & Outlook

The most material risk is margin compression. FY2025 net income of USD 0.98 billion on USD 10.401 billion of revenue is a 9.4% margin, and the FY2024 figure of USD 1.018 billion was lower despite revenue growth. Launch costs for ENCELTO, BRYTLY, and UNITY M will weigh on near-term profitability. A second risk is competitive intensity in contact lenses, where Johnson & Johnson Vision, Cooper Companies, and Bausch + Lomb can match promotional spending, limiting Alcon's ability to raise prices. Third, regulatory dependence is concentrated: the ENCELTO and BRYTLY launches depend on post-approval execution and reimbursement, and any delay in retinal or surgical device clearances would slow the shift toward higher-margin products.

The outlook is stable rather than transformative. Revenue growth from USD 9.911 billion in FY2024 to USD 10.401 billion in FY2025 was 4.9%, and sustaining that pace requires the new products to offset mature portfolio pressure. The balance sheet, with CHF 31.555 billion in assets and CHF 22.035 billion in equity at FY2025, provides room for further tuck-in acquisitions. VerityRank Score of 81/100.

Quick Facts

Headquarters

Geneva, Switzerland

Founded

1945

Employees

25000

Market cap

$37.5 B

Factories

Headquartered in Geneva, Switzerland, with primary operational and R&D campus in Fort Worth, Texas, USA, and 18 major manufacturing and R&D facilities across North America, Europe, and Asia.

Presence

Direct commercial presence in 56 countries serving over 260 million patients and consumers across more than 140 countries and territories worldwide.

Listing

SIX: ALC / NYSE: ALC
Categories
Biopharmaceutical

Related

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website SIX : ALC